Biotech and Pharmaceuticals Biotechnology

More

  • Fed hits social, tech stocks

    After Janet Yellen's comments on stretched valuations in the social media and biotech sectors, CNBC's Seema Mody looks at what stocks are taking the biggest hit.

  • Next global epidemic?

    CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.

  • Acorda 'firmly on the side of research': CEO

    Ron Cohen, Acorda Therapeutics CEO, discusses merger activity in the pharma sector and whether his company is planning an acquisition.

  • Biotech buys right now

    The S&P Biotech ETF is down 7 percent this week. Robyn Karnauskas, Deutsche Bank biotechnology director, shares her large and small cap picks.

  • Rough day for biotech

    CNBC's Meg Tirrell reports biotech stocks are performing lower than the broader markets.

  • Protect yourself from fake medicine

    CNBC's Scott Cohn follows up on his investigation into the high cost of prescription drugs and reports how consumers can protect themselves from getting fake medicine.

  • Incubating biotech's boom

    Quincy College in Massachusetts created a two year program to fill bio-manufacturing technician positions. CNBC's Mary Thompson reports how the school is fueling job growth.

  • Prescription drugs: Risk vs. cost

    Due to the high cost of prescription drugs, many in the U.S. look overseas to save money. CNBC's Scott Cohn discusses if people are putting themselves at risk or beating big drug companies at their own game.

  • Best time to buy Celgene, Vertex & more

    The biotech ETF soared 67 percent in 2013, but has since been bumpy. Discussing winning and losing stocks in the industry, with Mark Schoenebaum, ISI pharma/biotech analyst.

  • Bone disease breakthrough

    Emil Kakkis, Ultragenyx founder & CEO, discusses the beginning of its drug KRN23's phase 2 pediatric study to treat 30 kids with bone disorder X-linked hypophosphatemia (XLH).

  • Vertex CEO on big cystic fibrosis breakthrough

    CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."

  • Vertex soars on cystic fibrosis innovation

    CNBC's Meg Tirrell reports Vertex Pharmaceuticals' cystic fibrosis combination of Kalydeco and Lumacaftor has expanded their patient population.

  • Vertex's cystic fibrosis breakthrough

    CNBC's Meg Tirell reports Vertex Pharmaceuticals' treatment for cystic fibrosis has succeeded in late stage trials. Vertex will now file applications for U.S. and Europe approval in Q4.

  • Cubist advances Sivextro

    Michael Bonney, Cubist Pharmaceuticals CEO, discusses the FDA's approval of Sivextro, a new antibiotic designed to treat skin infections. Bonney also explains why so many pharma companies have left the antibiotic space.

  • Big event coming in biotech

    CNBC's Meg Tirrell reports on everything investors need to know about Vertex Pharmaceuticals' upcoming data release on a combination of drugs for cystic fibrosis.

  • Stéphane Bancel, president and founding CEO, Moderna Therapeutics

    AstraZeneca has invested $240 million in Moderna Therapeutics to license its technology, which uses messenger RNA therapy to fight cancer.

  • Medtronic moves to Ireland

    Medtronic announced that it has agreed to purchase Dublin, Ireland's Covidien for $42.9 billion in cash and stock. CNBC's Meg Tirrell discusses why this deal may be more about taxes than medical devices.

  • Analyzing Medtronic-Covidien deal

    Medtronic bought Covidien for $42.9 billion. Shagun Chadha, CRT Capital Group, discusses what this means for investors and explains the tax savings component of the transaction.

  • Merck's big buy

    CNBC's Meg Tirrell reports Merck is buying Idenix Pharmaceuticals for $3.85 billion. CNBC contributor Herb Greenberg provides insight on the important deal.

  • Expectations for new obesity drug

    New diet pill drug Contrave is expected to be approved by the FDA this week, reports CNBC's Meg Tirrell.